Below are the most recent publications written about "Platelet Glycoprotein GPIIb-IIIa Complex" by people in Profiles.
-
Orzalkiewicz M, Hodson J, Kwok CS, Ludman PF, Giblett JP, George S, Doshi SN, Khan SQ, Kinnaird T, Hildick-Smith D, Townend JN, Mamas MA, Calvert PA. Comparison of Routine Versus Selective Glycoprotein IIb/IIIa Inhibitors Usage in Primary Percutaneous Coronary Intervention (from the British Cardiovascular Interventional Society). Am J Cardiol. 2019 08 01; 124(3):373-380.
-
Olier I, Carr M, Curzen N, Ludman P, Baumbach A, Kinnaird T, de Belder MA, Hildick-Smith D, Sirker A, Kwok CS, Rashid M, Nolan J, Kontopantelis E, Mamas MA. Changes in Periprocedural Bleeding Complications Following Percutaneous Coronary Intervention in The United Kingdom Between 2006 and 2013 (from the British Cardiovascular Interventional Society). Am J Cardiol. 2018 09 15; 122(6):952-960.
-
Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, Frye SV, Shelton Earp H, DeRyckere D, Brass LF, Graham DK, Di Paola JA. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost. 2018 02; 16(2):352-363.
-
Sirker A, Mamas M, Robinson D, Anderson SG, Kinnaird T, Stables R, de Belder MA, Ludman P, Hildick-Smith D. Bivalirudin, glycoprotein inhibitor, and heparin use and association with outcomes of primary percutaneous coronary intervention in the United Kingdom. Eur Heart J. 2016 Apr 21; 37(16):1312-20.
-
Weintraub WS, Mandel L, Weiss SA. Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations. Pharmacoeconomics. 2013 Nov; 31(11):959-70.
-
Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26; 119(17):4066-72.
-
Naik MU, Stalker TJ, Brass LF, Naik UP. JAM-A protects from thrombosis by suppressing integrin aIIbß3-dependent outside-in signaling in platelets. Blood. 2012 Apr 5; 119(14):3352-60.
-
Yeung J, Apopa PL, Vesci J, Kenyon V, Rai G, Jadhav A, Simeonov A, Holman TR, Maloney DJ, Boutaud O, Holinstat M. Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation. Mol Pharmacol. 2012 Mar; 81(3):420-30.
-
Naik MU, Nigam A, Manrai P, Millili P, Czymmek K, Sullivan M, Naik UP. CIB1 deficiency results in impaired thrombosis: the potential role of CIB1 in outside-in signaling through integrin alpha IIb beta 3. J Thromb Haemost. 2009 Nov; 7(11):1906-14.
-
Hoekstra J, Cohen M, Giugliano R, Granger CB, Gurbel PA, Hollander JE, Manoukian SV, Saucedo JF, Pollack CV. Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention--an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. Am J Emerg Med. 2009 Jul; 27(6):720-8.